The ultimate control of cancer lies in the host’s immune surveillance and defense system. Moreover, an ideal tumor treatment modality should not only destroy the primary tumors, but also control metastases at distant sites.
For this reason, Immunotherapy, a treatment strategy designed to stimulate a patient's immune system to attack and destroy the tumors, has been considered a promising cancer treatment modality. Many new strategies have been proposed, including cytokine therapy, dendritic cell-based vaccines, and immune-activating antibodies, either alone or in various combinations with other therapies; however, thus far, these immunotherapy strategies have had low response rates, usually in the range of 5 to 10 percent among treated patients. Novel approaches are therefore needed to increase the efficacy of immunotherapies.
The objective of Immunophotonics is to introduce inCVAX, a novel and potentially very effective treatment for metastatic cancers, to cancer patients around the world who have no other option for cancer treatments. Our drug/device combination induces patient-specific immunity against the cancer, causing primary tumors and distant metastases to shrink or disappear. Pre-clinical product development is complete, and off-shore human pilot trials have yielded very promising results with significant tumor shrinkage and elimination.